Medical Marijuana Registry In Quebec Called World’s First


Share this Post:

Medical marijuana users in Quebec can now help shed light on the drug’s long-term safety and effectiveness through a new registry at McGill University in Montreal.

McGill says its medical marijuana registry, which launched on Monday, is the first research database of its kind in the world.

The registry meets a requirement of Quebec’s college of physicians, which considers cannabis an experimental therapy. Under provincial regulation, cannabis can only be prescribed as part of a formal study.

Health Canada estimates over 40,000 Canadians legally consume cannabis to relieve symptoms from diseases including multiple sclerosis, HIV, cancer or epilepsy.

An Initiative To Legalize Marijuana In California To Appear On Nov. Ballot

While cannabis has been studied for years as a recreational substance, little is known about its medical use, said Dr. Mark Ware, director of clinical research at McGill’s pain management unit.

“I got frankly tired of giving talks and presentations about the potential medical use of cannabis and always having questions for which I did not have answers,” said Ware. “I hope this study is a step in the direction of trying to fill some of these huge knowledge gaps.”

The registry allows doctors and users of medical marijuana to look for any possible safety concerns.

It will also allow researchers to look for clues about what variations of medical marijuana might work best for which conditions.

Combining information on the patients and the drugs could not only identify potential safety considerations but also start to answer questions about the effectiveness of cannabis under certain clinical conditions, Ware added.

Despite expanding access to medical marijuana globally, the university calls the project a world first. Ware said to his knowledge no country or region has set up such a prospective, formally approved clinical project.

The researchers hope to engage doctors on the front lines to participate in the research — an approach that could be adapted to study the safety and effectiveness of other drugs over the long term.

The data collected will not have any identifiable patient information to protect patient privacy.

As the Quebec registry ushers a phase where marijuana facts can be made available, do you think marijuana advocacy would increase or will it just hamper legalization issues for some countries?

via Joint Venture

Share this Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

Read more:
110215_Eaze On the Way to Becoming a Billion-Dollar Cannabis Biz
Eaze: On the Way to Becoming a Billion-Dollar Cannabis Biz

After raising $10 million last April for expansion purposes, Eaze is now looking to be one of the first billion-dollar...